Business, energy, technology, markets and global industry news from Business News Today

Ono Pharmaceutical

PharmaDeviceNews Ono Pharmaceutical
Bristol Myers Squibb is defending its multibillion-dollar Opdivo immunotherapy franchise as Amgen develops a proposed nivolumab biosimilar ahead of approaching United States patent expiry. Representative image.
Pharma & Biotech

Bristol Myers Squibb sues Amgen over Opdivo biosimilar as $10bn franchise nears patent cliff

Bristol Myers Squibb and Ono Pharmaceutical are suing Amgen over seven patents tied to its proposed Opdivo biosimilar ABP 206, opening an important legal battle around a cancer drug that generated more than $10 billion in 2025.

Read More
Representative image of oncologists reviewing advanced gastric cancer imaging in a modern cancer care setting, reflecting Ono Pharmaceutical’s ONO-4578 Phase 2 data and the race to improve first-line treatment for HER2-negative gastric and gastroesophageal junction cancer.
Pharma & Biotech

Can Ono and Deciphera turn ONO-4578 into a global Phase 3 oncology contender?

Ono’s ONO-4578 improved gastric cancer PFS in Phase 2. The next test is whether EP4 blockade can survive global Phase 3 scrutiny.

Read More